Compass Pathways Psilocybin Patent Upheld
BusinessCompass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.
Psychedelic Business Spotlight – June 17
Business, Stock ReportsThis week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!
The Four Psychedelics ETFs Capturing Investor Attention
BusinessDespite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to having different sized stakes companies, and their long-term success will vary.
Psychedelic Capitalism Takes a Trip to Davos
BusinessFrom May 21-26, for the first time, the Davos Forum will feature The House of Psychedelics. Here's why that matters for the psychedelics industry.
Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock Analysis
Business, EditorialOur resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks.
MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
Business, ResearchResearchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients.
Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis
BusinessWesana Health reaches a major strategic pivot point. Our resident Psychedelic Investor examines what this means for the company and industry at large.
Elon Musk Excites Psychedelic Industry CEOs with This Tweet
BusinessThis is one of the billionaire's most explicit acknowledgments of the power of psychedelics for mental health applications.
Why Field Trip Health Is Dividing in Two — and What This Means for Investors
BusinessField Trip Health plans to split into two independent, publicly traded companies: Field Trip Health and Wellness and Reunion Neuroscience.
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
BusinessOur resident Psychedelic Investor James Hallifax wonders if the "Shark Tank" star's prediction makes financial sense.